US98985Y1082
© Globe Newswire
12.01.2026
ZYME
LISTED
NYSE
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
News Preview
VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced appointments, promotions, retirements, and reductions to its leadership team intend...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.01.2026
ZYME
LISTED
NYSE
Zymeworks Outlines Strategic Priorities and Outlook for 2026
News Preview
VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significan...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ZYME
LISTED
NYSE
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
News Preview
VANCOUVER, British Columbia, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluati...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
02.12.2025
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Conferences
News Preview
• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
24.11.2025
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2025
ZYME
LISTED
NYSE
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
News Preview
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.11.2025
ZYME
LISTED
NYSE
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
News Preview
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced a novel strategic initiative focused on optimizing future cash flows from Ziihera® (...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.11.2025
ZYME
LISTED
NYSE
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
News Preview
VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced positiv...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2025
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that m...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2025
ZYME
LISTED
NYSE
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
News Preview
VANCOUVER, British Columbia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced prelim...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2025
ZYME
LISTED
NYSE
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
News Preview
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2025
ZYME
LISTED
NYSE
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
News Preview
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the ap...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
02.09.2025
ZYME
LISTED
NYSE
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
News Preview
VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced its d...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2025
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that m...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
ZYME
LISTED
NYSE
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
News Preview
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the ap...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.07.2025
ZYME
LISTED
NYSE
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
News Preview
VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the U....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2025
ZYME
LISTED
NYSE
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
News Preview
Company to participate in investor conferences in July and August Company to participate in investor conferences in July and August...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2025
ZYME
LISTED
NYSE
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
News Preview
VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that th...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that ma...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.05.2025
ZYME
LISTED
NYSE
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
News Preview
VANCOUVER, British Columbia, May 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the pre...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.04.2025
ZYME
LISTED
NYSE
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
News Preview
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.04.2025
ZYME
LISTED
NYSE
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
News Preview
VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.04.2025
ZYME
LISTED
NYSE
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
News Preview
VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.03.2025
ZYME
LISTED
NYSE
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
News Preview
VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today reported financ...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.02.2025
ZYME
LISTED
NYSE
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
News Preview
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced achieve...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that m...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
ZYME
LISTED
NYSE
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
News Preview
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the ap...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.02.2025
ZYME
LISTED
NYSE
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
News Preview
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that m...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.01.2025
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that m...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.11.2024
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming inv...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.11.2024
ZYME
LISTED
NYSE
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
News Preview
VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced, with Jazz Pharmaceuticals, that the U.S. Food and Drug Admini...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
ZYME
LISTED
NYSE
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
News Preview
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung ca...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
ZYME
LISTED
NYSE
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
News Preview
VANCOUVER, British Columbia, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported financial results for the three and nine months ended September...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
ZYME
LISTED
NYSE
Zymeworks Announces Participation in Upcoming Investor Conferences
News Preview
VANCOUVER, British Columbia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming inv...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.10.2024
ZYME
LISTED
NYSE
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
News Preview
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced new preclinical data for Zymeworks’ antibody-drug conjugate (A...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2024
ZYME
LISTED
NYSE
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
News Preview
VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed in the first-in-human Ph...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2024
ZYME
LISTED
NYSE
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
News Preview
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2024
ZYME
LISTED
NYSE
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
News Preview
Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.07.2024
ZYME
LISTED
NYSE
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
News Preview
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.06.2024
ZYME
LISTED
NYSE
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
News Preview
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2024
ZYME
LISTED
NYSE
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
News Preview
VANCOUVER, British Columbia, June 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Center for Drug Evaluation (CDE) of the National Medi...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
